Effectiveness of Nirsevimab in preventing Respiratory Syncytial Virus (RSV) infection in healthy infants
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on February 19th, 2024
|
Nirsevimab is a monoclonal antibody that targets the pre-fusion form of the F-protein on the respiratory syncytial virus (RSV). It has gained recent approval for use in the United States and the European Union for treating lower respiratory infections caused by RSV in children. Given its extended half-life, a study has explored the potential of Nirsevimab in preventing RSV infection among healthy children.
The study involved 8058 infants aged below 12 months, born with an average gestational age of 38 months. These infants were randomly divided into groups to receive either a placebo or Nirsevimab, administered intramuscularly at a dosage of 50 mg for infants weighing less than 5 kg and 100 mg for those weighing 5 kg or more. Upon the end of the study, the researchers determined that Nirsevimab exhibited an effectiveness rate of 83.2% in preventing lower respiratory infections associated with RSV. Furthermore, Nirsevimab significantly reduced the risk of severe infection by 75.7% and lowered the risk of hospitalization by approximately 80%.
The study involved 8058 infants aged below 12 months, born with an average gestational age of 38 months. These infants were randomly divided into groups to receive either a placebo or Nirsevimab, administered intramuscularly at a dosage of 50 mg for infants weighing less than 5 kg and 100 mg for those weighing 5 kg or more. Upon the end of the study, the researchers determined that Nirsevimab exhibited an effectiveness rate of 83.2% in preventing lower respiratory infections associated with RSV. Furthermore, Nirsevimab significantly reduced the risk of severe infection by 75.7% and lowered the risk of hospitalization by approximately 80%.